.svg)
Lilly Is Testing Retatrutide Head-to-Head Against Zepbound
TIME reports that Eli Lilly is directly comparing its two obesity drugs — with results due by early 2027 — and sees both as "future mainstays" of weight-loss treatment.
TIME
Our Take
Key points from the report
- Retatrutide is the first drug to target three hormones at once (GLP-1, GIP, and glucagon), versus one or two for current GLP-1 drugs.
- It helped people with obesity or overweight lose up to 28% of body weight over about 1.5 years — a level a Lilly executive compared to bariatric surgery.
- Even the lowest 4 mg dose produced ~19% loss, similar to the highest dose of Zepbound (tirzepatide).
- Lilly is running a direct head-to-head trial of tirzepatide vs retatrutide, with results expected late 2026 or early 2027.
- A Lilly executive described both drugs as likely long-term options rather than one making the other obsolete.
Where this fits
Your blogs compare retatrutide and tirzepatide using existing, separate trial data. This is different: it's news that a single trial pitting the two drugs directly against each other is underway. That's the study that could actually settle the comparison — and it hasn't reported yet. It's the "what's coming next" piece behind all the side-by-side numbers.
Retatrutide remains investigational and is not FDA-approved. A favorable comparison in a company trial, whenever it arrives, still isn't the same as approval or market availability.
Linked article remains the property of TIME · Reviewed for accuracy · Not affiliated with Eli Lilly
Register your interest in Retatrutide
Retatrutide is currently not available, but once it is approved, you’ll be the first to get notified. Sign up now and stay informed.
Simple one-time sign-up
Early access to availability updates
Exclusive status among the first users
Advantage over non-registered users
Disclaimer: This is not medical advice. Retatrutide is investigational and not FDA-approved. Consult your doctor. Full Medical Disclaimer.